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Activation of RhoA by Thrombin in
Endothelial Hyperpermeability
Role of Rho Kinase and Protein Tyrosine Kinases
Geerten P. van Nieuw Amerongen, Sanne van Delft, Mario A. Vermeer,
John G. Collard, Victor W.M. van Hinsbergh
Abstract—Endothelial cells (ECs) actively regulate the extravasation of blood constituents. On stimulation by vasoactive
agents and thrombin, ECs change their cytoskeletal architecture and small gaps are formed between neighboring cells.
These changes partly depend on a rise in [Ca21]i and activation of the Ca21/calmodulin-dependent myosin light chain
kinase. In this study, mechanisms that contribute to the thrombin-enhanced endothelial permeability were further
investigated. We provide direct evidence that thrombin induces a rapid and transient activation of RhoA in human
umbilical vein ECs. Under the same conditions, the activity of the related protein Rac was not affected. This was
accompanied by an increase in myosin light chain phosphorylation, the generation of F-actin stress fibers, and a
prolonged increase in endothelial permeability. Inhibition of the RhoA target Rho kinase with the specific inhibitor
Y-27632 reduced all of these effects markedly. In the presence of Y-27632, the thrombin-enhanced permeability was
additionally reduced by chelation of [Ca21]i by BAPTA. These data indicate that RhoA/Rho kinase and Ca21 represent
2 pathways that act on endothelial permeability. In addition, the protein tyrosine kinase inhibitor genistein reduced
thrombin-induced endothelial permeability without affecting activation of RhoA by thrombin. Our data support a model
of thrombin-induced endothelial permeability that is regulated by 3 cellular signal transduction pathways. (Circ Res.
2000;87:335-340.)
Key Words: human endothelial cells n RhoA n protein tyrosine kinases n calcium n phosphorylation
The endothelium is the main barrier for blood constituentsand actively regulates the extravasation of blood compo-
nents to the surrounding tissues. Formation of minute gaps
between endothelial cells (ECs), for instance during inflam-
mation, leads to extravasation of fluid and macromolecules
and may cause life-threatening edema. Analogous to smooth
muscle cell contraction, phosphorylation of the myosin light
chain (MLC) by the Ca21/calmodulin-dependent kinase I, the
classic MLC kinase, directs the actin-myosin–based contrac-
tion process in ECs and is dependent on calcium ions and
calmodulin.1 In addition to a Ca21/calmodulin-dependent
transient increase in permeability induced by histamine and
substance P,2 thrombin induces a prolonged disturbance of
endothelial barrier function.3 This is associated with a reori-
entation of the F-actin cytoskeleton, a prolonged MLC
phosphorylation, and the formation of intercellular gaps.4 In
contrast to smooth muscle cells, MLC phosphorylation in
ECs in vivo does not result in a general contraction of the
cells, but a contraction process does occur at the margins of
a cell.2
In the last few years it has become clear that MLC
phosphorylation is a highly regulated process in which small
G proteins of the Rho family play a crucial role. Most
attention has been paid to the small GTPase RhoA. In smooth
muscle cells, activation of RhoA results in “calcium sensiti-
zation”; ie, independently of changes in [Ca21]i, MLC phos-
phate levels increase by inhibition of the smooth muscle
myosin phosphatase, resulting in force generation.5 Other
proteins of the Rho family of small GTPases also could be
involved in MLC phosphorylation. Activation of the p21-ac-
tivated kinase (Pak), an enzyme that is activated by the small
G proteins Cdc42 and Rac, was shown to affect MLC
phosphorylation.6,7 In HeLa cells, overexpression of Pak
reduces MLC kinase activity.7 In contrast, in ECs Pak appears
to increase MLC phosphorylation by being an MLC kinase
itself.6,8
It is a matter of debate which Rho-like small GTPases are
involved in endothelial permeability. In human umbilical vein
ECs (HUVECs), the thrombin-induced endothelial hyperper-
meability was reduced by C3 transferase from Clostridium
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botulinum, a specific inhibitor of Rho.4,9 C3 transferase also
reduced the thrombin-induced MLC phosphorylation.4,9,10
Several investigators have doubted a role of RhoA in
thrombin-enhanced permeability11 or have suggested that Rac
participates in cytoskeletal remodeling by thrombin in ECs.12
In this study, we investigated whether thrombin induces an
activation of RhoA and Rac using 2 newly developed assays
for activation of RhoA13,14 and Rac.15 Protein tyrosine kinases
(PTKs) have been implicated in intracellular signaling in
thrombin-enhanced barrier dysfunction by many investiga-
tors.4,10,16,17 Because a genistein-sensitive PTK has been
reported to act upstream of RhoA in lysophosphatidic acid–
stimulated ECs,18 we subsequently studied whether PTKs
also are required for activation of RhoA by thrombin.
Furthermore, we evaluated the involvement of Rho kinase, a
downstream target of RhoA, in the thrombin-enhanced endo-
thelial permeability and MLC phosphorylation using the Rho
kinase inhibitor Y-27632.19,20
Materials and Methods
Materials
Cell culture reagents were obtained as described previously.4 Bovine
thrombin was from Leo Pharmaceutical Products. Horseradish per-
oxidase (HRP) was obtained from Sigma Chemical Company.
BAPTA–acetoxymethyl ester and rhodamine-phalloidin were from
Molecular Probes. Genistein was from Alexis Inc. Y-27632 was
supplied by Yoshitomi Pharmaceutical Industries. [32P]Orthophos-
phoric acid and Tran35S (a mixture of 35S-labeled amino acids) were
from ICN Pharmaceuticals, Inc. Antibody against Rho kinase was
provided by Dr L Lim (Institute for Molecular and Cell Biology,
Singapore).21 Antibody against RhoA was from Santa Cruz Biotech-
nology, Inc. Antibody against Rac was from Transduction Labora-
tories. Anti–platelet myosin Ig (nonmuscle) was from Sanbio.
Secondary antibodies were from Dakopatts.
Cell Culture and Evaluation of Barrier Function
HUVECs were isolated and cultured as previously indicated.22
Barrier function was evaluated by the transfer of HRP across
HUVEC monolayers grown on fibronectin-coated polycarbonate
filters of the Transwell system (Costar).4
MLC Phosphorylation
MLC phosphorylation was measured by a double labeling technique.
To that end, HUVECs were incubated for 24 hours with 150 mCi/mL
Tran35S label and for 2 hours with 150 mCi/mL [32P]orthophosphoric
acid in phosphate-free buffer before stimulation of the cells. Details
have been given previously.4
Rho Activity Assay
Rhotekin binding assays were essentially performed as de-
scribed.13,14 Briefly, 20 cm2 confluent HUVECs were preincubated
for 1 hour in medium 19911% human serum albumin (HSA). Cells
were stimulated and lysed. Lysates were cleared by centrifugation
and incubated with bacterially produced glutathione-S-transferase
(GST)—Rho binding domain of Rhotekin (RBD) immobilized on
glutathione-coupled Sepharose beads for 30 minutes at 40°C. Beads
were washed, eluted in Laemmli sample buffer, and analyzed by
Western blotting using a rabbit polyclonal anti-RhoA antibody.
Rac Activity Assay
Pak binding assays were performed as described.15 Confluent
HUVECs (20 cm2) were preincubated for 1 hour in medium
19911% HSA. Cells were stimulated and lysed. Lysates were
cleared by centrifugation and incubated with GST-Pak–Cdc42/rac1
interactive binding domain (CRIB, ie, the GTPase binding domain)
immobilized on glutathione-coupled Sepharose beads for 30 minutes
at 40°C. Beads were washed, eluted in Laemmli sample buffer, and
analyzed by Western blotting using a mouse monoclonal anti-Rac1
antibody.
Detection of Rho Kinase by Immunoblotting
Detection of Rho kinase by immunoblotting was performed as
indicated by Lim et al.21
Immunocytochemistry
The presence of F-actin was visualized by direct staining with
rhodamine-phalloidin and photographed using a digital Nikon Cool-
pix 900 camera. Total gap area was quantified from these pictures
using QWin image analysis software (Leica Imaging Systems).
Statistical Analysis
Data are reported as mean6SEM. Comparisons among .2 groups
were made by 1-way ANOVA, followed by the Bonferroni-adjusted
x2 test. Comparisons of time curves of 2 groups were made using
repeated-measures ANOVA. Individual group comparisons were
done using a Student t test for post hoc comparisons of the means.
Differences were considered significant at P,0.05.
Results
Activation of RhoA but Not Rac by Thrombin
To evaluate whether thrombin directly activates RhoA and
Rac in ECs, we used 2 newly developed assays for RhoA and
Rac activity. The assay for RhoA activity is based on binding
of activated RhoA (RhoA-GTP) to a GST-Rhotekin fusion
protein,13,15 which is reflected in the pull-down fraction of
Figure 1 (top). Under control conditions hardly any RhoA-
GTP could be detected. The amount of RhoA-GTP in the
pull-down fraction was greatly enhanced 30 seconds after
stimulation with 1 U/mL thrombin and diminished after 5
minutes. The overall amount of RhoA did not change (Figure
1, bottom). In contrast, the activity of Rac, which was
measured by use of a GST-Pak fusion protein,15 did not
change or even slightly decreased after thrombin stimulation
(Figure 1, middle). With the same reagents, activation of Rac
by bradykinin in rat PC12 cells was demonstrated previously
(see Reference 15). Thus, thrombin rapidly and transiently
activates RhoA but not Rac in HUVECs.
Figure 1. Thrombin transiently activates RhoA and has no effect
on Rac in human ECs. Top, Immunoblot showing activation of
RhoA after exposure of various time periods (in minutes) of
HUVECs to 1 U/mL thrombin. Cell lysates were incubated with
GST-RBD beads as described in Materials and Methods, the
beads were washed, and the bound protein was analyzed by
Western blotting using an antibody specific for RhoA. Middle,
Immunoblot showing that thrombin has no effect on Rac in the
same samples. Cell lysates were incubated with GST-Pak
beads. The bound protein was analyzed by Western blotting
using an antibody specific for Rac. Bottom, Before performing
the GST pull-down, 1/40 of each sample was analyzed on
Western blot using an antibody specific for RhoA, showing that
equal amounts of protein were present in all samples. Similar
results were obtained in 3 independent EC cultures.
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Rho Kinase Is Involved in the
Thrombin-Enhanced Permeability
To investigate whether RhoA acts in endothelial permeability
via Rho kinase, the cell-permeant Rho kinase inhibitor
Y-27632 was used at a high concentration of 10 mmol/L that
was shown to completely inhibit Rho kinase.19 We first
checked by Western blotting whether Rho kinase was present
in ECs and found 1 single band at the expected molecular
mass of 160 kDa in HUVECs (Figure 2A, inset) and other
types of human macro- and microvascular ECs (glomerular
and foreskin microvascular ECs, iliac artery and vein ECs,
and aorta ECs; data not shown). The Rho kinase inhibitor
Y-27632 was used to study the role of Rho kinase in the
thrombin-induced endothelial barrier dysfunction. Preincuba-
tion for 1 hour with 10 mmol/L Y-2763219 had no effect on
basal permeability (Figure 2A) but significantly attenuated
the thrombin-enhanced endothelial permeability, as evi-
denced by a decreased passage of the marker molecule HRP
through the endothelial monolayer. This attenuation was
partial, even when Y-27632 was used at a higher concentra-
tion (up to 100 mmol/L was tested, which had the same effect
as 10 mmol/L) or when its preincubation time was prolonged
to 3 hours (data not shown).
Inhibition of Rho kinase by Y-27632, which was maximal
at 10 mmol/L, together with chelation of intracellular Ca21
ions by BAPTA (Figure 2B), nearly completely blocked the
thrombin-enhanced HRP passage, suggesting that RhoA/Rho
kinase- and Ca21- dependent processes act on EC permeabil-
ity by separate pathways.
Inhibition of Rho Kinase Reduces MLC
Phosphorylation and Cytoskeletal Reorganization
Alterations in endothelial permeability are accompanied by
actin nonmuscle myosin interaction, which is regulated by
MLC phosphorylation. MLC phosphorylation, as determined
by 32P incorporation in MLC, was increased on activation of
ECs by thrombin in agreement with previous observations
(Figure 3).3,4,9,23 Preincubation with the Rho kinase inhibitor
Y-27632 significantly reduced MLC phosphorylation under
both basal and thrombin-stimulated conditions (Figure 3).
Formation of both thrombin-induced F-actin stress fibers and
Figure 2. Involvement of Rho kinase in thrombin-enhanced en-
dothelial permeability. A, Effect of the Rho kinase inhibitor
Y-27632 on the passage of HRP through HUVEC monolayers
under basal conditions (E, ) and after exposure to 1 U/mL
thrombin (F, ). Cells were preincubated for 1 hour in medium
19911% HSA without (E, F) or with 10 mmol/L Y-27632 (, ),
and HRP passage was measured as described in Materials and
Methods. Values are mean6SEM of 9 cultures in 3 independent
experiments. The interaction between time and Y-27632 treat-
ment was significant (P50.000) for thrombin-stimulated cells.
Treatment with Y-27632 resulted in lower HRP passage com-
pared with no treatment. *P,0.05, Y-27632-pretreated vs non-
pretreated cells that were stimulated with thrombin. Inset,
Detection of Rho kinase by Western blot in HUVEC extracts.
Estimated molecular mass of the protein was 160 kDa. B, Effect
of BAPTA and Y-27632 on basal (open bars) and thrombin-
induced HRP passage (solid bars) across HUVEC monolayers.
Cells were pretreated for 1 hour with 3 mmol/L BAPTA,
10 mmol/L Y-27632, or both. HRP passage was measured 2
hours after sham treatment or exposure to 1 U/mL thrombin.
Values are mean6SD of 6 cultures in 2 experiments. *P,0.05,
cells pretreated with BAPTA or Y-27632 vs nonpretreated cells.
#P,0.05, cells pretreated with a combination of BAPTA and
Y-27632 vs pretreatment with each compound alone.
Figure 3. MLC phosphorylation is inhibited by Y-27632. A,
Autoradiograph of MLCs immunoprecipitated from cells under
basal conditions (2) and 10 minutes after stimulation with 1
U/mL thrombin (1). Cells were labeled with 32P and 35S as
described previously4 and preincubated with 10 mmol/L
Y-27632 for 1 hour. MLC phosphorylation was measured as
described in Materials and Methods. Top, Exposure in which a
filter was present to block 35S signal. Bottom, Exposure without
filter. B, Quantification of MLC phosphorylation. Shown is effect
of 10 mmol/L Y-27632 on basal (open bars) and thrombin-
enhanced (solid bars) MLC phosphorylation. The level of 32P
incorporation into MLCs was calculated relative to the amount
of 35S incorporation into MLCs of the same sample, as was
described previously.4 Values are mean6SEM of 3 different cul-
tures in duplicate. *P,0.05 Y-27632–pretreated vs nonpre-
treated cells.
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small gaps between neighboring ECs was significantly pre-
vented by Y-27632 (Figure 4). Thus, activation of Rho kinase
by thrombin is involved in the thrombin-induced MLC
phosphorylation and is required for the proper formation of
stress fibers and small gaps.
Inhibition of PTKs Reduces Thrombin-Induced
Permeability but Not RhoA Activation
To investigate whether the PTKs involved in endothelial
permeability act upstream of Rho activation, ECs were
preincubated for 1 hour with 30 mg/mL of the PTK inhibitor
genistein. This dose of genistein is a maximally effective dose
for inhibiting endothelial barrier dysfunction.4 Genistein did
not affect the thrombin-induced activation of RhoA (Figure 5,
inset). In parallel cultures genistein, but not its inactive
analogue daidzein (data not shown; see also Reference 4),
inhibited the thrombin-enhanced passage of HRP through the
endothelial monolayer (Figure 5). This indicates that the
genistein-sensitive PTKs, which are involved in endothelial
barrier dysfunction, do not act upstream of RhoA activation.
Subsequently, endothelial monolayers were coincubated with
genistein and Y-27632 to test whether PTKs act downstream of
Rho kinase in inducing endothelial barrier dysfunction. The
inhibition of the thrombin-induced HRP passage by genistein
was in addition to the inhibition by Y-27632 (Figure 5). This
indicates that a PTK-dependent process also acts on a RhoA/Rho
kinase-independent pathway that affects EC permeability.
Discussion
In the present study, we provide direct evidence that thrombin
potently activates RhoA in ECs but does not affect the
activity of Rac. Activity of the PTKs involved in endothelial
hyperpermeability was not required for the thrombin-induced
activation of RhoA. Furthermore, it was shown that thrombin
increases endothelial permeability via Rho kinase indepen-
dently from a rise in [Ca21]i and that PTKs and Rho kinase
have additive effects on endothelial hyperpermeability.
To our knowledge, we provide the first direct demonstra-
tion that RhoA is activated by thrombin in confluent endo-
thelial monolayers. Its rapid onset was comparable with the
rise in [Ca21]i. However, RhoA activation extended beyond
the transient (5-minute) rise in [Ca21]i; some RhoA-GTP was
still detectable after 30 minutes. Under basal conditions,
hardly any active RhoA was detectable, suggesting that
RhoA, unless activated, has little or no effect on basal barrier
integrity. Previous studies indirectly suggested the involve-
ment of RhoA in endothelial permeability largely on the basis
of the use of C3 transferase. This toxin penetrates the cell
with difficulty and requires long preincubation times. Thus, it
may interfere with gene regulation. Other investigators have
used toxin B, which inhibits RhoA, Rac, and Cdc42. Inacti-
vation of RhoA, Rac, and Cdc42 disrupts the endothelial
barrier,24 whereas inactivation of RhoA alone enhances en-
dothelial barrier function.11 It is therefore likely that toxin B
does not exert its disruptive effect via RhoA, but acts either
via Rac or Cdc42.
In addition to RhoA, thrombin-enhanced endothelial per-
meability requires Ca21-ions.4,9 Similarly, as previously
found with the Rho inhibitor C3 transferase, inhibition of Rho
kinase inhibited the increased permeability, but only partly at
Figure 5. Effect of genistein and Y-27632 on basal (open bars) and
thrombin-enhanced (solid bars) permeability. Endothelial monolay-
ers were pretreated for 1 hour with 30 mg/mL genistein, 10 mmol/L
Y-27632, or both. HRP passage was determined 1 hour after sham
treatment or exposure to 1 U/mL thrombin. Values are mean6SD
of 6 cultures in 2 experiments. *P,0.05, cells pretreated with
genistein or Y-27632 vs nonpretreated cells. #P,0.05, cells pre-
treated with a combination of genistein and Y-27632 vs pretreat-
ment with each compound alone. Inset, Genistein has no effect on
thrombin-induced activation of RhoA. HUVECs were preincubated
with 30 mg/mL genistein for 1 hour and stimulated with 1 U/mL
thrombin for 1 minute. Western blot of the pull-down of activated
RhoA and 1/40 of total RhoA is shown.
Figure 4. Y-27632 reduces thrombin-induced cytoskeletal reorga-
nization and gap formation. A, Immunocytochemical staining of
F-actin in HUVECs grown on glass cover slips. ECs were preincu-
bated for 1 hour in medium 19911% HSA in the absence (a and
b) or the presence (c and d) of 10 mmol/L Y-27632 and stimulated
for 30 minutes with 1 U/mL thrombin (b and d). Gaps between
cells are indicated with black arrows in panels b and d. B, Quantifi-
cation of endothelial gap formation. Gap area is expressed as a
percentage of total area covered by ECs grown on glass cover
slips. Y-27632 significantly reduced thrombin-induced gap forma-
tion. *P,0.05. Values are mean6SEM of 3 independent experi-
ments with HUVEC cultures from different donors.
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the maximally effective dose of Y-27632. In combination
with the chelation of Ca21 ions, Y-27632 almost completely
prevented the thrombin-induced HRP passage. This indicates
not only that both Ca21 ions and the RhoA/Rho kinase
pathway are necessary for the full thrombin response but also
that RhoA/Rho kinase signaling and Ca21-dependent pro-
cesses additionally contribute barrier dysfunction.
MLC phosphorylation plays a pivotal role in initiating actin-
myosin interaction and in the development of barrier dysfunc-
tion.4 Here, we extend our previous observation on RhoA4 and
show that Rho kinase contributes to MLC phosphorylation in
ECs. This is comparable with the situation in smooth muscle
cells25 and blood platelets,26–28 in which Rho kinase has recently
been shown to be involved in MLC phosphorylation. Rho kinase
can increase MLC phosphorylation by inhibiting the myosin
phosphatase.29 It is likely that the same mechanism of Rho
kinase–induced MLC phosphorylation acts in ECs, as it was
shown that in ECs the myosin phosphatase is inhibited by
thrombin30,31 and that the inhibition of Rho by C3 transferase
prevents the inhibition of the phosphatase induced by thrombin.9
In addition to an effect on MLC phosphorylation, Rho kinase
also phosphorylates other proteins. Several of these proteins are
involved in stress fiber formation and may act on EC barrier
function, including LIM kinase,32 adducin, and members of the
ERM (ezrin/radixin/moesin) family.33 Their involvement in
endothelial permeability remains to be demonstrated. The con-
tribution of additional factors activated by Rho cannot be
excluded. Phosphatidylinositol 4,5-biphosphate (PIP2) may be
involved, as intracellular levels of PIP2 can be increased after
activation of Rho34 and PIP2 is known to interfere with the actin
cytoskeleton.35
We have shown previously that, in addition to a rise in
intracellular Ca21 ions, PTKs are involved in the thrombin-
enhanced endothelial barrier dysfunction.4 Other investiga-
tors demonstrated that a genistein-sensitive PTK acts up-
stream of lysophosphatidic acid–induced RhoA activation in
ECs.18 The present study shows that inhibition of PTKs with
genistein does not influence activation of RhoA by thrombin,
indicating that PTKs do not act upstream of the activation of
RhoA in thrombin-enhanced endothelial permeability. This
suggests differences between activation of RhoA by either
lysophosphatidic acid or thrombin, which may be the involve-
ment of G13. G13 is involved in the activation of RhoA by
lysophosphatidic acid but has not been demonstrated to be
involved in thrombin-induced signal transduction.36
Inhibition of PTKs with genistein reduced the thrombin-
enhanced barrier dysfunction in addition to the effect of
Y-27632. This indicates that PTKs and Rho kinase at least act
by separate pathways. Interestingly, this study and our pre-
vious study show that chelation of Ca21 by BAPTA acts in
addition to the inhibition of both PTKs and Rho kinase. This
suggests that the Ca21-, RhoA-, and PTK-mediated pathways
induced by thrombin reflect separate pathways and that all
converge in increased permeability. For the RhoA- and
Ca21-dependent pathways, this convergence point is probably
the MLC phosphorylation (compare Figure 6, left).
Inhibition of PTKs may act on endothelial permeability by
various mechanisms. PTK inhibitors attenuate agonist-induced
increases in [Ca21]i.37,38 In accordance with this, Garcia et al10
recently reported that activity of an EC-specific MLC kinase is
regulated by tyrosine phosphorylation in a RhoA-dependent
manner. However, additional mechanisms must exist, as PTKs
are involved in endothelial barrier dysfunction independent of
changes in [Ca21]i4 and RhoA signaling (present study). A likely
mechanism is the destabilization or disruption of junctions by
tyrosine phosphorylation of junctional proteins. Tyrosine phos-
phorylation of occludin and ZO-1 can occur under conditions of
hyperpermeability.39 The agonist-induced disruption of adherens
junctions is accompanied by tyrosine phosphorylation of vascu-
lar endothelial cadherin (VE-cadherin) and the associated
catenins, resulting in the dissociation of VE-cadherin/
catenins.40,41 Disintegration of junctional complexes and the
actin-nonmuscle myosin interaction in the periphery of ECs may
thus act in concert in prolonged thrombin-induced endothelial
permeability (Figure 6).
Our data point to an important role for RhoA and Rho kinase
in the regulation of endothelial permeability. Future studies have
to demonstrate whether and when these factors are involved in
altered endothelial barrier function in vivo. In large-vessel ECs,
in particular in areas with altered shear forces, stress fibers are
found and Rho-mediated processes are likely to be involved. The
recent finding of Essler et al,42 that mildly oxidized LDL
activates Rho/Rho kinase signaling in ECs, suggests the involve-
ment of RhoA and Rho kinase in vascular leakage during the
development of atherosclerosis. No information is presently
available on microvascular ECs in vivo. However, it should be
noticed that Rho kinase plays a role in cell migration and that
prolonged permeability might be a reflection of the altered
behavior of ECs during cell migration and angiogenesis, which
occur in wound healing and pathological conditions.
Figure 6. Proposed mechanisms involved in thrombin-induced
endothelial barrier dysfunction. Thrombin induces Ca21-
dependent activation of MLC kinase as well as RhoA/Rho kinase–
dependent inhibition of the myosin phosphatase. Both facilitate
MLC phosphorylation, which causes an increased actin-myosin
interaction, and a contraction process at the margins of the
cells, which finally results in a disturbed endothelial barrier func-
tion. In addition to Ca21- and RhoA-dependent processes,
thrombin-induced PTK activities act on phosphorylation of junc-
tional proteins as VE-cadherin and its associated catenins,
which results in disruption of intercellular junctions.40 CaM indi-
cates calmodulin; MLCK, MLC kinase; MLC-P, phosphorylated
MLC; and PP1M, myosin phosphatase type 1.
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